Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Xenon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 98Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xenon Presents 48-Month Azetukalner OLE Data for Epilepsy at AES
    Xenon Presents 48-Month Azetukalner OLE Data for Epilepsy at AES

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200741/33485/en/Xenon-Showcases-New-48-Month-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    Xenon To Unveil Azetukalner OLE Study Results In Epilepsy At AES
    Xenon To Unveil Azetukalner OLE Study Results In Epilepsy At AES

    25 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3194314/33485/en/Xenon-to-Present-New-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html

    GLOBENEWSWIRE
    25 Nov 2025
    Share Share
    Xenon appoints Darren Cline as Chief Commercial Officer
    Xenon appoints Darren Cline as Chief Commercial Officer

    24 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/24/3104214/33485/en/Xenon-Announces-Appointment-of-Darren-Cline-as-Chief-Commercial-Officer.html

    GLOBENEWSWIRE
    24 Jun 2025
    Share Share
    Xenon to Present at Stifel 2025 Virtual CNS Forum
    Xenon to Present at Stifel 2025 Virtual CNS Forum

    12 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/12/3041733/33485/en/Xenon-to-Present-at-Stifel-2025-Virtual-CNS-Forum.html

    GLOBENEWSWIRE
    12 Mar 2025
    Share Share
    Xenon Reports Q2 2024 Financial Results and Business Update
    Xenon Reports Q2 2024 Financial Results and Business Update

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2927285/33485/en/Xenon-Reports-Q2-2024-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Xenon Pharma: Phase 2 Azetukalner Data In Depression At ASCP 2024
    Xenon Pharma: Phase 2 Azetukalner Data In Depression At ASCP 2024

    28 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/28/2889029/33485/en/Xenon-Pharmaceuticals-Presents-Data-from-Phase-2-X-NOVA-Clinical-Trial-of-Azetukalner-in-Major-Depressive-Disorder-at-the-American-Society-of-Clinical-Psychopharmacology-2024-Annua.html

    GLOBENEWSWIRE
    28 May 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.